{
    "Trade/Device Name(s)": [
        "SEKURE HbA1c Assay"
    ],
    "Submitter Information": "SEKISUI DIAGNOSTICS P.E.I. INC.",
    "510(k) Number": "K173206",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130255"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ",
        "LCP"
    ],
    "Summary Letter Date": "May 31, 2018",
    "Summary Letter Received Date": "June 4, 2018",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1373",
        "21 CFR 864.7470"
    ],
    "Regulation Name(s)": [
        "Hemoglobin A1c Test System"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "hematology"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole blood",
        "Hemolysate"
    ],
    "Specimen Container(s)": [
        "Dipotassium EDTA tube",
        "Tripotassium EDTA tube",
        "Sodium Fluoride/Disodium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "SK500 Clinical Chemistry System"
    ],
    "Method(s)/Technology(ies)": [
        "Enzymatic assay"
    ],
    "Methodologies": [
        "Enzymatic quantification"
    ],
    "Submission Type(s)": [
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for SEKURE HbA1c Assay, an enzymatic assay on the SK500 for percent hemoglobin A1c measurement in whole blood and hemolysate.",
    "Indications for Use Summary": "Measures percent concentration of hemoglobin A1c (NGSP) or HbA1c fraction mmol/mol (IFCC) in human venous whole blood and hemolysate on the SK500 Clinical Chemistry System to aid in diabetes diagnosis, identification of at-risk patients, and monitoring of long-term blood glucose control.",
    "fda_folder": "Clinical Chemistry"
}